Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration Clinical Trial

— CAPTAIN  

Official title:

Correlation of Functional and Structural Outcomes With Serum Antibody Profiles in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02843490
• Other study ID #: 469055
• Status: Completed
• Phase: Phase 4
• First received: July 21, 2016
• Last updated: November 30, 2017
• Start date: August 5, 2016
• Est. completion date: November 9, 2017

Study information

• Verified date: November 2017
• Source: Johannes Gutenberg University Mainz
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Several studies during the last years reported the involvement of anti-retinal autoantibodies in ocular disorders, such as AMD. These studies support the growing evidence of an immunological involvement in the pathogenesis of AMD. In the planned trial it is planned to enroll 70 subjects, i.e. 50 subjects with neovascular AMD and 20 healthy volunteers. The investigators will evaluate the change from Baseline (Visit 1) in BCVA score at Week 12 (visit 4) in the study eye of nAMD patients treated with Ranibizumab. Neovascular AMD patients (group 1) will be accompanied for 6 months and blood samples will be collected at baseline and monthly until Visit 7 for analysis of antibody profiles. Healthy volunteers (group 2) will be enrolled and a blood sample will be collected once for analysis of antibody profiles. Antibody profiles of all study participants will be analysed to address questions as defined in the outcome measures.

Description:

Several studies during the last years reported the involvement of anti-retinal autoantibodies in ocular disorders, such as retinal vasculitis, retinopathy, retinitis pigmentosa and also AMD. These studies support the growing evidence of an immunological involvement in the pathogenesis of AMD. In the planned trial it is planned to enroll 70 subjects, i.e. 50 subjects with neovascular AMD and 20 healthy volunteers. The investigators will evaluate the change from Baseline (Visit 1) in BCVA score at Week 12 (visit 4) in the study eye of nAMD patients treated with Ranibizumab. AMD patients and healthy volunteers will be recruited at the Department of Ophthalmology of the University Medical Center, Johannes Gutenberg-University Mainz and included based on defined criteria. Neovascular AMD patients (group 1) will be accompanied for 6 months and blood samples will be collected at baseline and monthly until Visit 7 for analysis of antibody profiles. Ranibizumab is applied according to the manufacturer's recommendations and the "Stellungnahme der DOG, RG und BVA zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären AMD" (December 2012). A loading dose of three injections within the first three months is followed by an individual therapy interval based on the clinical progress (PRN). Re-treatment after the upload of the three initial doses every 4 weeks will be performed in case of progression (PRN) based on the recommendations of the "Stellungnahme der DOG, RG und BVA zu aktuellen therapeutischen Möglichkeiten bei der neovasculären AMD" (December 2012). Healthy volunteers (group 2) will be enrolled and a blood sample will be collected once for analysis of antibody profiles.

Beside the analysis of primary endpoint, the investigators propose to analyze in detail the following questions:

Does the ranibizumab treatment have any effects on antibody profiles found in sera and do these changes correlate with the clinical course of the disease?

Additionally, the patient group can be divided into two subgroups: AMD patients with newly diagnosed neovascular AMD, who have not received anti-VEGF-treatment so far (naïve subjects) and AMD patients with neovascular AMD, who have not received any anti-VEGF treatment 3 months prior to inclusion in the study. This separation may help to answer the question if it is possible to differentiate between ranibizumab responder and non-responder with the help of antibody profiles.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 71
• Est. completion date: November 9, 2017
• Est. primary completion date: August 17, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria (patients):

• Male or female

• Age = 50 years

• Subfoveal, juxtafoveal and/or extrafoveal choroidal neovascularisation due to neovascular age-related macular degeneration in the study eye

• Visual acuity of 20/400 (ETDRS charts) or better in the study eye

• Ability of subject to understand character and individual consequences of clinical Trial

• Signed and dated informed consent of the subject must be available before start of any specific trial procedures

• Women with childbearing potential have to practice a medically accepted contraception during trial and a negative pregnancy test (urine) should be existent before trial. Reliable contraception are systematic contraceptives (oral, implant, injection) and diaphragm or condoms with spermicide. Women that are sterile by surgery or for more than two years postmenopausal can participate in the trial.

Inclusion Criteria (healthy subjects):

• Male or female

• Age = 50 years

Exclusion Criteria (patients):

• Inability to obtain fluorescein angiography

• Ophthalmic Surgery or laser < 3 months before enrolment in one or both eyes

• Any history of intravitreal steroids in one or both eyes

• Systemic and/or intravitreal anti-VEGF-treatment < 3 months before enrolment in one or both eyes

• Patients with hypersensitivity against ranibizumab

• Ocular inflammation (including trace or above) or external ocular inflammation in the study eye

• Inability to give informed consent to participate in the study

• Pregnancy and lactation; Woman who are of childbearing age and not using medically acceptable effective contraception.

• Medical or psychological condition that would not permit completion of the trial or signing of informed consent (legal representative accepted)

• Participation in other clinical trials including an investigational drug or device during the present clinical trial or within the last 4 weeks.

Exclusion Criteria (Healthy subjects):

• Ophthalmic Surgery or laser < 3 months before enrolment

• Relevant eye diseases except age-related cataract in one or both eyes

• Inability to give informed consent to participate in the study

• Pregnancy and lactation; Woman who are of childbearing age and not using medically acceptable effective contraception.

• Medical or psychological condition that would not permit completion of the trial or signing of informed consent (legal representative accepted)

• Participation in other clinical trials including an investigational drug or device during the present clinical trial or within the last 4 weeks

Related Conditions & MeSH terms

• Macular Degeneration
• Neovascular Age-related Macular Degeneration
• Wet Macular Degeneration

Intervention

Drug:
• Ranibizumab
Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)

Locations

Country	Name	City	State
Germany	Clinical Trial Site, Department of Ophthalmology, University Medical Center Johannes Gutenberg University Mainz	Mainz

Sponsors (2)

Lead Sponsor	Collaborator
Johannes Gutenberg University Mainz	Novartis

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Identification of biomarkers against retinal antigens	Identification of antibodies (biomarkers) against retinal antigens (anti cyclophilin B, heat shock protein (HSP) 10, HSP 70) in patients with neovascular AMD treated with ranibizumab and healthy subjects.	24 weeks
Other	Validation of biomarkers	Validation of antibodies (biomarkers) against retinal antigens (anti cyclophilin B, heat shock protein (HSP) 10, HSP 70) in patients with neovascular AMD treated with ranibizumab and healthy subjects found in previous studies.	24 weeks
Other	Correlation of functional and structural parameters	To correlate functional and structural parameters (BCVA and central retinal thickness) with the identified biomarkers to differentiate between initial and deferred responders.	24 weeks
Primary	Change in BCVA	Change from Baseline (Visit 1) in BCVA score at Week 12 (visit 4) in the study eye.	Baseline - 12 weeks
Secondary	Change in BCVA	Change from Baseline (Visit 1) in BCVA score at Week 24 (visit 7) in the study eye.	Baseline - 24 weeks
Secondary	Change in retinal thickness	Absolute change from baseline (Visit 1) in central retinal thickness, assessed by OCT at Week 24 (Visit 7) in the study eye.	Baseline - 24 weeks
Secondary	Number of ranibizumab injections	Mean number of IVT ranibizumab injections needed up to Week 24 (Visit 7) in the study eye.	24 weeks